Clinical Research Studies

The purpose of the RNS System LGS Feasibility Study is to show that the NeuroPace RNS® System medical device is safe well and effective (works well) as an additional treatment in reducing the frequency of generalized seizures in individuals with LGS, Lennox-Gastaut Syndrome, who are 12 years of age or older. Specifically, people participating have LGS, seizures not controlled by antiseizure medications, and frequent and disabling drop seizures (atonic, tonic, tonic-clonic, and/or myoclonic seizures).

The federal Food and Drug Administration (FDA) has approved the RNS System for use in patients 18 years and older with hard-to-treat focal onset seizures. The RNS System is being used in this research and is considered investigational.